Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
December 09, 2024 16:01 ET
|
Chimerix, Inc.
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024 16:01 ET
|
Chimerix, Inc.
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement...
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
November 11, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
November 07, 2024 07:00 ET
|
Chimerix, Inc.
– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review...
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
November 01, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2024 16:31 ET
|
Chimerix, Inc.
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 13, 2024 07:00 ET
|
Chimerix, Inc.
– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose...
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
August 06, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...